NewcelX (NCEL) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quantum Biopharma (QNTM) has outperformed NewcelX (NCEL) over the past year, losing 80.3% versus a loss of 83.3%. Over five years, QNTM leads with a -96.7% price change compared with -99.7% for NCEL. Quantum Biopharma is the larger company by market cap ($20.0 million vs $17.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCEL | QNTM |
|---|---|---|
| Share price | $3.02 | $3.11 |
| Market cap | $17.44M | $20.00M |
| 1-day change | -2.89% | +0.00% |
| YTD return | +63.68% | -57.40% |
| 1-year return | -83.32% | -80.28% |
| 5-year return | -99.68% | -96.65% |
| P/E ratio (TTM) | 5.81 | — |
| EPS (TTM) | $0.52 | $-4.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.60 | $16.36 |
| 52-week low | $1.83 | $2.07 |
| Distance from 52-week high | -83.76% | -80.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +661.59% | +294.52% |
| Average volume | 10.28K | 205.30K |
| Shares outstanding | 5.78M | 6.43M |
| Employees | 9 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
NCEL vs QNTM FAQ
Which is bigger, NewcelX or Quantum Biopharma?
Quantum Biopharma (QNTM) is larger, with a market capitalization of $20.00M compared with $17.44M for NewcelX (NCEL).
Which stock has performed better over the past year, NCEL or QNTM?
QNTM returned -80.28% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are NewcelX and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.